Ambazone

Template:Chembox ECNumberTemplate:Chembox E numberTemplate:Chembox AppearanceTemplate:Chembox SolubilityInWater

Ambazone

Names
IUPAC name [4-(2-(Diaminomethylidene)hydrazinyl)phenyl]iminothiourea
Other names 2-[4-[(aminoiminomethyl)hydrazono]-2,5-cyclohexadien-1-ylidene]-Hydrazinecarbothioamide; (4-Oxo-2,5-cyclohexadien-1-ylideneamino)guanidine thiosemicarbazone; 1,4-Benzoquinone amidinohydrazone thiosemicarbazone; Ambazon; Anginon; Benzoquinone guanylhydrazone thiosemicarbazone; Faringosept; Guanothiazon; Inversal; Inversal; Ivertol; N-Guanidino-N'-thioureido-p-benzoquinonediimide; Primal; p-Benzoquinone amidinohydrazone thiosemicarbazone;Faringosept (TN); Ambazone (INN); OAMBAZONE; Ambazonum [INN-Latin]; Ambazona [INN-Spanish]; Ambazone [INN:BAN:DCF]; CCRIS 1926; MLS001240207
Identifiers
CAS Number	539-21-9 Y
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL2103762
ChemSpider	12232507 Y
ECHA InfoCard
KEGG	D07376 Y
PubChem CID	1549158
UNII	BYK4592A3Q Y
InChI InChI=1S/C8H11N7S/c9-7(10)14-12-5-1-3-6(4-2-5)13-15-8(11)16/h1-4H,(H4,9,10,14)(H3,11,15,16)/b12-5-,13-6+ Y Key: MLMFUKWWZIZRHX-UWRPRBHNSA-N Y InChI=1/C8H11N7S/c9-7(10)14-12-5-1-3-6(4-2-5)13-15-8(11)16/h1-4H,(H4,9,10,14)(H3,11,15,16)/b12-5-,13-6+ Key: MLMFUKWWZIZRHX-UWRPRBHNBF
SMILES NC(=S)N\N=C1\C=C/C(=N\NC(N)=N)/C=C1
Properties
Chemical formula	C8H11N7S
Molar mass	237.28 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Y verify (what is YN ?)
Infobox references

WikiDoc Resources for Ambazone
Articles
Most recent articles on Ambazone Most cited articles on Ambazone Review articles on Ambazone Articles on Ambazone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ambazone Images of Ambazone Photos of Ambazone Podcasts & MP3s on Ambazone Videos on Ambazone
Evidence Based Medicine
Cochrane Collaboration on Ambazone Bandolier on Ambazone TRIP on Ambazone
Clinical Trials
Ongoing Trials on Ambazone at Clinical Trials.gov Trial results on Ambazone Clinical Trials on Ambazone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ambazone NICE Guidance on Ambazone NHS PRODIGY Guidance FDA on Ambazone CDC on Ambazone
Books
Books on Ambazone
News
Ambazone in the news Be alerted to news on Ambazone News trends on Ambazone
Commentary
Blogs on Ambazone
Definitions
Definitions of Ambazone
Patient Resources / Community
Patient resources on Ambazone Discussion groups on Ambazone Patient Handouts on Ambazone Directions to Hospitals Treating Ambazone Risk calculators and risk factors for Ambazone
Healthcare Provider Resources
Symptoms of Ambazone Causes & Risk Factors for Ambazone Diagnostic studies for Ambazone Treatment of Ambazone
Continuing Medical Education (CME)
CME Programs on Ambazone
International
Ambazone en Espanol Ambazone en Francais
Business
Ambazone in the Marketplace Patents on Ambazone
Experimental / Informatics
List of terms related to Ambazone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ambazone is an oral antiseptic.

Ambazon was patented in 1957 by Bayer under the trade name Iversal, and briefly used in Germany. It is still used in Russia, countries of the former Soviet Union and Romania. It has not been approved by the United States Food and Drug Administration (FDA).

Synthesis

Ambazone can be obtained in a two step synthetic method, reacting 1,4-Benzochinone with Aminoguanidine and Thiosemicarbazide.,

Obtaining a pharmacetical grade material is difficult due to high amounts of byproducts, synthetic intermediates and decomposition products.

Applications

Bacteriostatic action on hemolytic streptococcus, streptococcus pneumoniae and viridans streptococcus.

Physical properties

Through experimental testing ambazone has shown antiseptic properties, along with anti-tumor properties. Ambazone has the following physical characteristics.

Table 1. Physical properties
Dark brown
Odorless
Tasteless
Powder
Melting Point 192–194 °C (decomp.)

Table 2. Solubility	per 100 ml
Water	0.2 mg
Methanol	0.5 mg
Chloroform	0.3 mg
1-butanol	6.5 mg
Ethyl acetate	17 mg
Acetone	50 mg
Ethanol	85 mg
Dimethyl formamide	1.7 g
sulfoxide	2.5 g

Table 3. Uv-Vis	nm
Water	403
Alcohols	440-445
Ethyl acetate	453
Dimethyl sulfoxide	467

Ambazone is prepared by way of solid based crystallization or grinding.

Mode of action

The mode of action for ambazone has been studied extensively and ambazone has been shown to react via different methods. Ambazone shows low mutagenic activity and no cardiovascular, CNS, metabolic, or gastrointestinal side-effects with I.V. doses up to 10-5 mol/kg and oral doses up to 10-3 mol/kg. As stated before ambazone can be administered via oral or I.V. administration, but the problem with oral administration is that one experimental study shows there is only a 35-50% absorption while another study shows 40% in the intestines; These results would tend to lead the reader to think that ambazone would not be the best choice for treatment, because with such a low absorbance, there is going to have to be a greater concentration ingested to gain a positive effect from the drug. The problem with a greater concentration is that ambazone has a half-life of 6–7 hours. It was stated above that ambazone possess no CNS side-effects and the reason we know this is, due to the fact, that it will not cross the blood brain barrier. Although this is the body’s way of protecting unwanted substances from attacking the brain, this also limits the treatment of brain tumors with ambazone.

Therapeutic uses

The therapeutic properties of ambazone were studied in lab rats and the therapeutic dose was determined to be 60–125 mg/kg of body weight. As stated above, ambazone possesses anti-septic properties shown by its increased activity against gram-positive cocci. Along with anti-septic properties, ambazone has also shown its ability to fight forms of leukemia in lab rats. When administered orally the results showed prolongation of life expectancy and curing of L1210 and P388 leukemia in lab rats. Scientist used different methods to determine the results, such as; mean survival time (MST), percent increase of life span, survival rates, percent change in body weights and number of peritoneal cells. The results gathered show tremendous strides towards leukemia treatment. Although we can see positive results, one might wonder, “Are there side effects?” The results show different answers depending on the test performed. When testing ambazone via AMES with no metabolic activation we find there are no mutagenic or carcinogenic properties. When the same test is performed with metabolic activation or when the C-Test is performed we do see the potential for mutagenicity. The results show two different paths and until further testing has been performed we cannot determine if the good outweighs the bad when it comes to using ambazone for treatment.